These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 12807368)
1. Direct treatment costs for patients with lung cancer from first recurrence to death in france. Braud AC; Lévy-Piedbois C; Piedbois P; Piedbois Y; Livartovski A; Le Vu B; Trédaniel J; Reboul F; Brewer Y; Talbi S; Blanchon F; Paschen B; Durand-Zaleski I Pharmacoeconomics; 2003; 21(9):671-9. PubMed ID: 12807368 [TBL] [Abstract][Full Text] [Related]
2. Diagnostic and therapeutic approaches to lung cancer in Canada and their costs. Evans WK; Will BP; Berthelot JM; Wolfson MC Br J Cancer; 1995 Nov; 72(5):1270-7. PubMed ID: 7577481 [TBL] [Abstract][Full Text] [Related]
3. Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom: A retrospective observational study (LuCaBIS). Andreas S; Chouaid C; Danson S; Siakpere O; Benjamin L; Ehness R; Dramard-Goasdoue MH; Barth J; Hoffmann H; Potter V; Barlesi F; Chirila C; Hollis K; Sweeney C; Price M; Wolowacz S; Kaye JA; Kontoudis I Lung Cancer; 2018 Oct; 124():298-309. PubMed ID: 29961557 [TBL] [Abstract][Full Text] [Related]
4. Management and costs of treating lung cancer patients in a university hospital. Dedes KJ; Szucs TD; Bodis S; Joerger M; Lowy A; Russi EW; Steinert HC; Weder W; Stahel RA Pharmacoeconomics; 2004; 22(7):435-44. PubMed ID: 15137882 [TBL] [Abstract][Full Text] [Related]
5. Estimation of lung cancer diagnosis and treatment costs based on a patient-level analysis in Catalonia (Spain). Corral J; Espinàs JA; Cots F; Pareja L; Solà J; Font R; Borràs JM BMC Health Serv Res; 2015 Feb; 15():70. PubMed ID: 25889153 [TBL] [Abstract][Full Text] [Related]
6. Treatment pathways, resource use and costs in the management of small cell lung cancer. Oliver E; Killen J; Kiebert G; Hutton J; Hall R; Higgins B; Bourke S; Paschen B Thorax; 2001 Oct; 56(10):785-90. PubMed ID: 11562518 [TBL] [Abstract][Full Text] [Related]
7. Direct costs associated with the disease management of patients with unresectable advanced non-small-cell lung cancer in The Netherlands. Pompen M; Gok M; Novák A; van Wuijtswinkel R; Biesma B; Schramel F; Stigt J; Smit H; Postmus P Lung Cancer; 2009 Apr; 64(1):110-6. PubMed ID: 18805601 [TBL] [Abstract][Full Text] [Related]
8. Estimating the cost of lung cancer diagnosis and treatment in Canada: the POHEM model. Evans WK; Will BP; Berthelot JM; Wolfson MC Can J Oncol; 1995 Dec; 5(4):408-19. PubMed ID: 8770457 [TBL] [Abstract][Full Text] [Related]
9. Changing costs of metastatic non small cell lung cancer in the Netherlands. Keusters WR; de Weger VA; Hövels A; Schellens JHM; Frederix GWJ Lung Cancer; 2017 Dec; 114():56-61. PubMed ID: 29173766 [TBL] [Abstract][Full Text] [Related]
10. Costs of non-small cell lung cancer in the Netherlands. van der Linden N; Bongers ML; Coupé VM; Smit EF; Groen HJ; Welling A; Schramel FM; Uyl-de Groot CA Lung Cancer; 2016 Jan; 91():79-88. PubMed ID: 26589654 [TBL] [Abstract][Full Text] [Related]
11. Cost effectiveness of modified fractionation radiotherapy versus conventional radiotherapy for unresected non-small-cell lung cancer patients. Ramaekers BL; Joore MA; Lueza B; Bonastre J; Mauguen A; Pignon JP; Le Pechoux C; De Ruysscher DK; ; Grutters JP J Thorac Oncol; 2013 Oct; 8(10):1295-307. PubMed ID: 24457241 [TBL] [Abstract][Full Text] [Related]
12. Economic analysis of carboplatin versus cisplatin in lung and ovarian cancer. Khan ZM; Rascati KL; Koeller JM Pharmacoeconomics; 1999 Jul; 16(1):43-57. PubMed ID: 10539121 [TBL] [Abstract][Full Text] [Related]
13. Epidemiology and treatment costs of bone metastases from lung cancer: a French prospective, observational, multicenter study (GFPC 0601). Decroisette C; Monnet I; Berard H; Quere G; Le Caer H; Bota S; Audigier-Valette C; Geriniere L; Vernejoux JM; Chouaid C; J Thorac Oncol; 2011 Mar; 6(3):576-82. PubMed ID: 21270669 [TBL] [Abstract][Full Text] [Related]
14. Metastatic non-small cell lung cancer: costs associated with disease progression. Fox KM; Brooks JM; Kim J Am J Manag Care; 2008 Sep; 14(9):565-71. PubMed ID: 18778171 [TBL] [Abstract][Full Text] [Related]
15. Cost analysis of lung cancer management in South Western Sydney. Kang S; Koh ES; Vinod SK; Jalaludin B J Med Imaging Radiat Oncol; 2012 Apr; 56(2):235-41. PubMed ID: 22498199 [TBL] [Abstract][Full Text] [Related]
16. Estimation of the additional costs of chemotherapy for patients with advanced non-small cell lung cancer. Maslove L; Gower N; Spiro S; Rudd R; Stephens R; West P Thorax; 2005 Jul; 60(7):564-9. PubMed ID: 15994264 [TBL] [Abstract][Full Text] [Related]
17. A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer. Nuijten MJ; de Castro Carpeño J; Chouaid C; Vergnenègre A; Grossi F; Bischoff H; Heigener D; Walzer S Lung Cancer; 2012 Jun; 76(3):465-71. PubMed ID: 22153602 [TBL] [Abstract][Full Text] [Related]
18. Cost of combined modality interventions for stage III non-small-cell lung cancer. Evans WK; Will BP; Berthelot JM; Earle CC J Clin Oncol; 1997 Sep; 15(9):3038-48. PubMed ID: 9294466 [TBL] [Abstract][Full Text] [Related]
19. Economics of the clinical management of lung cancer in France: an analysis using a Markov model. Chouaïd C; Molinier L; Combescure C; Daurès JP; Housset B; Vergnenègre A Br J Cancer; 2004 Jan; 90(2):397-402. PubMed ID: 14735183 [TBL] [Abstract][Full Text] [Related]
20. Brain metastases in patients with ALK+ non-small cell lung cancer: clinical symptoms, treatment patterns and economic burden. Guérin A; Sasane M; Zhang J; Culver KW; Dea K; Nitulescu R; Wu EQ J Med Econ; 2015 Apr; 18(4):312-22. PubMed ID: 25565443 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]